Skip to main content

Table 3 Unit costs for model treatments

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Drug acquisition costs Dosing and frequency Unit cost, GBP
177Lu-Dotatate 7.4 GBq (200 mCi) (Lutathera) 4 administrations of 7.4 GBq (200 mCi), administered once every 8 weeks 71,500 (for 4 administrations)
Octreotide LAR 60 mg/ 30 mg administered once every 28 days 1 × 30 mg vial, 998.41
Everolimus (Afinitor) 10 mg administered once daily 1 × 30 tab pack (10 mg), 2673
Sunitinib (Sutent) 37.5 mg administered once daily 1 × 30 tab pack (12.5 mg), 784.70
  1. Costs of medications administered prior to or concomitantly with 177Lu-Dotatate (i.e. anti-emetics and amino acids) were also included in the analysis with data on doses and frequency of administration sourced from clinical trials